Women with PMOS should get subsidised weight-loss drugs: Australian advocates
Factors mentioned by advocates include high costs and access to PBS that is not equitable; experts are calling for further research.
Australian advocates say women with PMOS should get subsidised weight-loss drugs for PMOS through the Pharmaceutical Benefits Scheme (PBS). They say that they should be available on a medical basis, not because they can pay hundreds of dollars per month.
Why PMOS Needs Wider Attention
Previously known as polycystic ovary syndrome (PCOS), PMOS is a metabolic and hormonal disorder that impacts more than 170 million women globally, or about 1 in every 8 women. The 2026 name change acknowledges that it impacts more than just the ovaries.
Symptoms are irregular periods, excess body hair, acne, hair loss and weight issues and fertility problems. UNSW research has also found that PMOS can increase the risk of developing type 2 diabetes and heart disease and endometrial cancer.
Why Advocates Want Drug Costs Reduced
The Australian advocacy group, POSAA, is seeking GLP-1 medicines to be included on the PBS for those with PMOS. Lorna Berry, who was diagnosed at 32, said it would be better to have access regardless of location or birthplace in the country, in POSAA’s view. Several hundred dollars a month can be the cost of treatment, and some women don’t have the money for it.
A July 2026 UNSW Sydney study estimated about 500,000 Australians regularly used GLP-1 medicines. Nearly half paid from their own pocket for use outside diabetes treatment (A200 – A700). That was a low-end figure, as it didn’t account for drugs that are marketed for weight loss, such as Wegovy and Saxenda, researchers said.
What the Medicines Do
GLP-1 medicines mimic a natural hormone that helps control blood sugar and appetite. Ozempic and Wegovy both contain semaglutide, but Wegovy has a higher dose. In Australia, Ozempic is subsidised through the PBS only for eligible people with type 2 diabetes. Wegovy is approved for chronic weight management, but wider PBS funding remains unresolved.
In November 2025, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended a subsidy for people with a body mass index above 35. That recommendation did not create a PBS listing, and a revised proposal is due for review in November 2026.
These medicines are not specifically approved by Australia’s Therapeutic Goods Administration to treat PMOS, so prescribing them for the condition itself is off-label. Associate Professor Magdalena Simonis of the Royal Australasian College of Physicians said the college has no current position on their use for PMOS and stressed that other treatment options exist.
Why More Research Matters
QENDO, which supports people affected by PMOS and other women’s health conditions, says early evidence suggests possible benefits for some patients, but more research is needed to understand long-term safety and effectiveness specifically for PMOS. POSAA is also seeking research funding alongside fairer access.
Any PBS listing must balance affordability with strong evidence. GLP-1 medicines also require medical advice and monitoring. For women with PMOS, the issue is recognition of a complex condition and access to evidence-based care.
Explore the latest health trends, global security developments, historic milestones and market movements.
Why Are GLP-1 Drugs Gaining Attention?
Discover why Americans are paying more attention to GLP-1 weight-loss drugs and their potential effects.
Can Ecuador Defeat Its Powerful Drug Gangs?
Explore how Ecuadorian police are tackling powerful gangs, gun violence and corruption.
What Should Americans Know About Flu?
Check out the latest flu symptoms, vaccine updates and key information for the 2026–2027 season.
Who Is Algeria’s First Woman Speaker?
Discover how Khalida Boufedeche made history with her election as Algeria’s first woman parliamentary speaker.
Why Are Copper Prices Falling Now?
Find out how easing supply tightness and the upcoming Federal Reserve rate decision are influencing copper prices.
